AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. View recent trades and share price information for AstraZeneca plc (AZN) Ordinary US$0.25 Short Volume is a data set that can be used to understand investor sentiment. AstraZeneca plc este o companie farmaceutică anglo-suedeză cu peste 66.000 de angajați, ale cărei produse acoperă o gamă largă de afecțiuni: cardiace, vasculare, respiratorii, neurologice, etc. AZN's forecast earnings growth (22.1% per year) is above the. Stable Share Price: AZN is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 3% a week. Earnings vs Market: AZN's earnings (22.1% per year) are forecast to grow slower than the UK market (22.2% per year). AZN's earnings (22.1% per year) are forecast to grow slower than the UK market (22.2% per year). Dilution of Shares: Shareholders have not been meaningfully diluted in the past year. AstraZeneca PLC's company bio, employee growth, exchange listings and data sources, AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastro... Show more. Astrazeneca (AZN) share price, charts, trades & the UK's most popular discussion forums. Here's Why AstraZeneca (LON:AZN) Can Manage Its Debt Responsibly. Significantly Below Fair Value: AZN is trading below fair value by more than 20%. AZN's dividend payments have increased over the past 10 years. You can change your choices at any time by visiting Your Privacy Controls. Find the latest ASTRAZENECA PLC ORD SHS $0.25 (AZN.L) stock quote, history, news and other vital information to help you with your stock trading and investing. Free forex prices, toplists, indices and lots more. AZN exceeded the UK Pharmaceuticals industry which returned 3.5% over the past year. What is AstraZeneca current dividend yield, its reliability and sustainability? PB vs Industry: AZN is overvalued based on its PB Ratio (8.1x) compared to the GB Pharmaceuticals industry average (4.4x). Please read our Financial Services Guide before deciding whether to obtain financial services from us. AZN's revenue (9.9% per year) is forecast to grow slower than 20% per year. Debt Coverage: AZN's debt is well covered by operating cash flow (21.8%). AZN (£69.51) is trading below our estimate of. is forecast to be very high in 3 years time (45.7%). ASTRAZENECA PLC AZN Company page - Search stock, chart, recent trades, company information, trading information, company news, fundamentals View the latest Astrazeneca (AZN) share price and news, including recent trades, historical charts, broker views and our views. How Does AstraZeneca PLC (LON:AZN) Fare As A Dividend Stock? AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastro, Unless specified all financial data is based on a yearly period but updated quarterly. Earnings vs Industry: AZN earnings growth over the past year (139%) exceeded the Pharmaceuticals industry -11.3%. More Details, Trading at 48.6% below our estimate of its fair value, Earnings are forecast to grow 22.1% per year, Dividend of 2.9% is not well covered by earnings, Large one-off items impacting financial results. The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. Mr. Soriot has been the Chief Executive Officer and Executive Dir. Annual General Meeting. Dividend Coverage: With its high payout ratio (114.9%), AZN's dividend payments are not well covered by earnings. Explore growth companies in the Pharmaceuticals & Biotech industry. Follow AZN. Who are the major shareholders and have insiders been buying or selling? Reducing Debt: AZN's debt to equity ratio has increased from 81.2% to 140.9% over the past 5 years. AstraZeneca PLC discovers, develops, and … PE vs Market: AZN is poor value based on its PE Ratio (39.7x) compared to the UK market (25.1x). AstraZeneca PLC AZN financial information, fundamentals, key ratios, market capitalization, shares outstanding, float, and short interest. Astrazeneca News Headlines. Stable Dividend: AZN's dividends per share have been stable in the past 10 years. Reasonable growth potential average dividend payer. AZN's dividends per share have been stable in the past 10 years. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.AZN dividend payout ratio is more than 90% making it difficult for the company to maintain the dividends and increase it year by year. Mr. Pascal Soriot, M.B.A., D.V.M., had been Independent Non-Executive Director at CSL Limited since August 19, 2020 until January 31, 2021. How has AstraZeneca performed over the past 5 years? Future ROE: AZN's Return on Equity is forecast to be very high in 3 years time (45.7%). To help ensure the safety and security of our workforce and shareholders during the COVID-19 pandemic, the AGM took place behind closed doors in compliance with the ‘Stay at Home Measures’ passed into law in England and Wales on 26 March 2020. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. , this metric is skewed due to their high level of debt. Can AstraZeneca PLC's (LON:AZN) ROE Continue To Surpass The Industry Average? Explore more healthy companies in the Pharmaceuticals & Biotech industry. WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"), of the important March 29, 2021 lead plaintiff deadline. AZN underperformed the UK Market which returned 27.8% over the past year. Pascal's compensation has been consistent with company performance over the past year. ET by MarketWatch Automation Italy approves AstraZeneca’s COVID-19 vaccine for over 65s Mr. Pascal Soriot, M.B.A., D.V.M., had been Independent Non-Executive Director at CSL Limited since August 19, 2020 until January 31, 2021. The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. Return vs Market: AZN underperformed the UK Market which returned 27.8% over the past year. AZN's dividends in 3 years are forecast to be well covered by earnings (39.3% payout ratio). AstraZeneca PLC ADR outperforms market on strong trading day Mar. PEG Ratio: AZN is poor value based on its PEG Ratio (1.8x). Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry. have bought more shares than they have sold in the past 3 months. AZN earnings growth over the past year (139%) exceeded the Pharmaceuticals industry -11.3%. The AstraZeneca PE ratio based on its reported earnings over the past 12 months is 52.71.The shares are currently trading at SEK848.9.. AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Return vs Industry: AZN exceeded the UK Pharmaceuticals industry which returned 3.5% over the past year. AZN's revenue (9.9% per year) is forecast to grow faster than the UK market (6.5% per year). Emerging Markets are key to the ongoing pipeline- and sales-driven transformation of AstraZeneca. Reasonable growth potential average dividend payer. The AstraZeneca share price stands out as one of the FTSE 100’s top blue-chip shares based on its recent performance. $49.01 -$0.80 -1.6% Price as of March 11, 2021, 6:27 p.m. EST View Interactive AZN Charts. Future Dividend Coverage: AZN's dividends in 3 years are forecast to be well covered by earnings (39.3% payout ratio). AZN's earnings growth over the past year (139%) exceeds its 5-year average (-7.7% per year). High Growth Earnings: earnings are expected to grow significantly over the next 3 years. Debt Level: AZN's debt to equity ratio (140.9%) is considered high. Financial News Articles for Astrazeneca Plc Ord Shs $0.25 updated throughout the day. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. ($USD21.09M) is above average for companies of similar size in the UK market ($USD3.80M). Should you invest in AstraZeneca (LSE:AZN)? AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. Find out more about how we use your information in our Privacy Policy and Cookie Policy. Growing Dividend: AZN's dividend payments have increased over the past 10 years. AstraZeneca’s 2020 Annual General Meeting (AGM) took place on 29 April 2020. AZN's dividend (2.9%) is low compared to the top 25% of dividend payers in the UK market (4.41%). Astrazeneca PLC Description. 337927). How experienced are the management team and are they aligned to shareholders interests? How volatile is AstraZeneca's share price compared to the market and industry in the last 5 years? AstraZeneca (AZN) closes a deal with the European Commission for supplying at least 400 million doses of its COVID-19 vaccine, AZD1222, if approved. Accelerating Growth: AZN's earnings growth over the past year (139%) exceeds its 5-year average (-7.7% per year). AZN AstraZeneca PLC Denmark and Norway Suspend Use of AstraZeneca Vaccine Over Blood Clot Worries. Notable Dividend: AZN's dividend (2.9%) is higher than the bottom 25% of dividend payers in the UK market (1.45%). Experienced Management: AZN's management team is seasoned and experienced (7.8 years average tenure). AZN / AstraZeneca Plc short volume is shown in the following chart. Information about your device and internet connection, including your IP address, Browsing and search activity while using Verizon Media websites and apps. Yahoo is part of Verizon Media. Experienced Board: AZN's board of directors are considered experienced (7.3 years average tenure). Interest Coverage: AZN's interest payments on its debt are well covered by EBIT (6.3x coverage). Earnings vs Savings Rate: AZN's forecast earnings growth (22.1% per year) is above the savings rate (1%). Astrazeneca Plc Ord Shs $0.25 is listed on the London Stock Exchange, trading with ticker code AZN. Stock analysis for AstraZeneca PLC (AZN:London) including stock price, stock chart, company news, key statistics, fundamentals and company profile. When an investor makes a short sale, they do so with the belief that a security will decline in price. AZN's short term assets ($19.5B) do not cover its. Learn more. 8, 2021 at 4:55 p.m. High Growth Revenue: AZN's revenue (9.9% per year) is forecast to grow slower than 20% per year. than 75% of UK stocks over the past 3 months. High ROE: Whilst AZN's Return on Equity (20.1%) is high, this metric is skewed due to their high level of debt. Earnings Trend: AZN's earnings have declined by 7.7% per year over the past 5 years. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. (114.9%), AZN's dividend payments are not well covered by earnings. Is AstraZeneca undervalued compared to its fair value and its price relative to the market? AstraZeneca PLC (AZN) Nasdaq Global Select. AZN AstraZeneca PLC AstraZeneca Warns Europe of Large Delivery Shortfall, Blaming Export Curbs ... AZN AstraZeneca News . Quality Earnings: AZN has a large one-off gain of $977.0M impacting its December 31 2020 financial results. To enable Verizon Media and our partners to process your personal data select 'I agree', or select 'Manage settings' for more information and to manage your choices. ... ASX … 48.40-0.27 ... and ASX … Interesting Read: AstraZeneca (LON: AZN) vaccine rollout gets extended to general practitioners AstraZeneca had agreed to deliver about 80 million doses to the 27 EU countries by the end of March, but on 22 January, it announced that it was cutting the same by 60 per cent due to production delays. Growing Profit Margin: AZN's current net profit margins (12%) are higher than last year (5.5%). (39.7x) compared to the UK market (25.1x). AZN's debt to equity ratio has increased from 81.2% to 140.9% over the past 5 years. AZN Share News. Long Term Liabilities: AZN's short term assets ($19.5B) do not cover its long term liabilities ($30.8B). High Dividend: AZN's dividend (2.9%) is low compared to the top 25% of dividend payers in the UK market (4.41%). The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.AZN dividend payout ratio is more than 90% making it difficult for the company to maintain the dividends and increase it year by year. AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. Find the latest Astrazeneca PLC (AZN) stock quote, history, news and other vital information to help you with your stock trading and investing. The AstraZeneca PE ratio based on its reported earnings over the past 12 months is 51.05.The shares are currently trading at $49.27.. AZN. PE vs Industry: AZN is poor value based on its PE Ratio (39.7x) compared to the GB Pharmaceuticals industry average (38.9x). Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry. 11/03/2021 05:23:29 1 … gain of $977.0M impacting its December 31 2020 financial results. Learn more here. Revenue vs Market: AZN's revenue (9.9% per year) is forecast to grow faster than the UK market (6.5% per year). Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. Last updated 2021/03/09 20:12 Over the past years, our global sales base has changed from having most of sales coming from what we now call ‘Other’ medicines to our current setup where our business is focused on three main therapy areas: Oncology, New Cardiovascular, Renal & Metabolism, and Respiratory & Immunnology. It opened the day at US$49.41 after a previous close of US$48.19. Insider Buying: AZN insiders have bought more shares than they have sold in the past 3 months. Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. AstraZeneca PLC paid £2.80 dividend and the ex-dividend date was 25 Feb 2021.The dividend payout ratio is 115.00%. Stock analysis for AstraZeneca PLC (AZN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Explore strong past performing companies in the Pharmaceuticals & Biotech industry. ROSEN, A LEADING LAW FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline – AZN. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Astrazeneca plc - ADR share forecasts, stock quote and buy / sell signals below.According to present data Astrazeneca plc - ADR's AZN shares and potentially its market environment have been in a bullish … It has a market capitalisation of £92,035m, with approximately 1,313m shares in issue. How has AstraZeneca's share price performed over time and what events caused price changes? Astrazeneca | AZN Stock Price | Live Quote | Historical Chart. (8.1x) compared to the GB Pharmaceuticals industry average (4.4x). Unless specified all financial data is based on a yearly period but updated quarterly. The latest AstraZeneca plc (AZN) Ordinary US$0.25 share price (AZN). Mr. Soriot has been the Chief Executive Officer and Executive Dir... Show more. Volatility Over Time: AZN's weekly volatility (3%) has been stable over the past year. All other quotes are delayed by at least 15 minutes unless otherwise stated. AZN's earnings have declined by 7.7% per year over the past 5 years. Astrazeneca plc - ADR () Stock Market info Recommendations: Buy or sell Astrazeneca plc - ADR stock? The equity has been one … (39.7x) compared to the GB Pharmaceuticals industry average (38.9x). AZN is trading below fair value by more than 20%. AstraZeneca PLC (AZN) is a leading drug manufacturers-general business with stocks listed in the US. AZN's dividend (2.9%) is higher than the bottom 25% of dividend payers in the UK market (1.45%). How is AstraZeneca forecast to perform in the next 1 to 3 years based on estimates from 18 analysts? Executive Vice-President of Operations & Information Technology, Executive VP of Human Resources & General Counsel, Executive VP of Sustainability & Chief Compliance Officer, Executive Vice-President of BioPharmaceuticals Research & Development, Executive Vice-President of BioPharmaceuticals Business Unit, Executive VP of International & China President, Executive Vice-President of Europe & Canada, Senior Independent Non-Executive Director. Compensation vs Market: Pascal's total compensation ($USD21.09M) is above average for companies of similar size in the UK market ($USD3.80M). Below Fair Value: AZN (£69.51) is trading below our estimate of fair value (£135.17). Invest with The Share Centre Short Term Liabilities: AZN's short term assets ($19.5B) do not cover its short term liabilities ($20.3B). ... NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes. AstraZeneca (NYSE:AZN) declares second interim dividend of $1.90/share, bringing total annual dividend to $2.80, unchanged from the prior year … We and our partners will store and/or access information on your device through the use of cookies and similar technologies, to display personalised ads and content, for ad and content measurement, audience insights and product development. Compensation vs Earnings: Pascal's compensation has been consistent with company performance over the past year. AstraZeneca PLC paid $2.80 dividend and the ex-dividend date was 24 Feb 2021.The dividend payout ratio is 114.75%.